

Yisheng expands with new business divisions in Cambodia

20 July 2018 | News

The two divisions represent the first expansion of Yisheng Biopharma business and product sales operations into an ASEAN member country



Yisheng Biopharma Co., Ltd. ("Yisheng Biopharma"), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, announced the grand opening of Anderson Biotech Company Limited and Royal OncoCare Hospitality as two wholly owned subsidiaries of Yisheng Biopharma in Cambodia.

The two divisions represent the first expansion of Yisheng Biopharma business and product sales operations into an ASEAN member country.

"The opening of these two divisions is an important milestone in company history," commented Zhang Yi, Founder and Chairman of Yisheng Biopharma. "Our product Yivyka™ is approved in Cambodia for the treatment of advanced solid tumors, including lung, breast, liver, colorectal and stomach cancers. We are pleased to be in a position to expand access to the benefits that this product will bring to cancer patients and are grateful for the support we have received from the Ministry of Health of the Kingdom of Cambodia."

Yivyka™ is an innovative immuno-oncology drug recently granted a drug registration license by the Ministry of Health of the Kingdom of Cambodia. Yivyka™ is the first biological product introduced into the Cambodia market by Yisheng Biopharma.